Monday, September 25, 2006 Overview of Process and Structure |
9:00am - 9:15am |
Welcome and Introduction |
Justina A. Molzon, M.S. Pharm., J.D.
Associate Director
International Programs
CDER, FDA |
9:15am - 9:45am |
FDA in the International Community |
Justina A. Molzon, M.S. Pharm., J.D.
Associate Director
International Programs
CDER, FDA
Beverly Corey, DVM
Director
International Relations Staff
Office of International Programs
Office of the Commissioner, FDA |
9:45am - 10:30am |
CDER's Center Director |
Steven K. Galson
Director
CDER, FDA |
10:30am - 11:00am |
Break |
|
11:00am - 12:00pm |
Drug Review and Related Activities in the United States |
Mary E. Kremzner, Pharm.D.
Deputy Director
Division of Drug Information
Office of Training and Communications
CDER, FDA |
12:00pm - 1:30pm |
Lunch |
|
1:30pm - 2:15pm |
Advisory Committees |
Igor Cerny, Pharm.D.
Director
Advisors and Consultants Staff
Office of Executive Programs
CDER, FDA |
2:15pm - 3:15pm |
Drug Review Process Overview |
Dena Hixon, M.D.
Associate Director for Medical Affairs
Office of Generic Drugs
Office of Pharmaceutical Science CDER, FDA |
3:15pm - 3:30pm |
Break |
|
3:30pm - 3:50pm |
Ombudsman |
Warren Rumble
Ombudsman
CDER, FDA |
3:50pm - 4:15pm |
Training Reviewers |
Janice Newcomb
Director
Division of Training and Development
Office of Training and Communications
CDER, FDA |
4:15pm - 5:00pm |
The Role of CDER's Office of Business Process Support |
Gary M. Gensinger, MBA
Director
Regulatory Review Support Staff
Office of Business Process Support
CDER, FDA |
Tuesday, September 26, 2006 Application Review |
9:00am - 9:15am |
Welcome |
Justina A. Molzon, M.S. Pharm., J.D.
Associate Director
International Programs
CDER, FDA |
9:15am - 9:30am |
Good Guidance Practices |
Nancy Derr
Writer/Editor/Policy Analyst
Office of Regulatory Policy
CDER, FDA |
9:30am - 10:00am |
Good Review Practices |
Howard D. Chazin, M.D., M.B.A
Medical Officer
Guidance and Policy Team
Office of New Drugs
CDER, FDA |
10:00am - 11:00am |
Overview of the Office of New Drugs |
Kim Colangelo
Associate Director for Regulatory Affairs
Office of New Drugs
CDER, FDA |
11:00am - 11:15am |
Break |
|
11:15am - 12:15pm |
Labeling |
Jeanne Delasko
Label Initiatives Specialist
Office of New Drugs
CDER, FDA |
12:15pm - 1:45pm |
Lunch |
|
1:45pm - 2:00pm |
Photo |
|
2:00pm - 3:30pm |
Panel of Discipline Roles |
Discipline Panel |
3:30pm - 3:45pm |
Break |
|
3:45pm - 4:25pm |
Specialty Reviews - Biologics |
David Ross
Associate Director For Regulatory Science
Office Of Oncology Drug Products
Office Of New Drugs
CDER, FDA |
4:25pm - 4:45pm |
Specialty Reviews - Pediatrics - US |
Jean Temeck, M.D.
Acting Medical Team Leader
Pediatric and Maternal Health Staff
Immediate Office
Office of New Drugs, FDA
Rosemary Addy, M.H.S.
Regulatory Health Project Manager
Pediatric and Maternal Health Staff
Office of New Drugs
CDER, FDA |
4:45pm - 5:15pm |
Regulation of Over-the-Counter Drugs |
Leah Christl, Ph.D.
Regulatory Project Manager and Acting Chief
Project Management Staff
Office of Nonprescription Products
Office of New Drugs
CDER, FDA |
Wednesday, September 27, 2006 Compliance: Good Clinical Practices (GCP), Good Manufacturing Practices (GMP) |
9:00am - 9:05am |
Welcome |
Justina A. Molzon, M.S. Pharm., J.D.
Associate Director
International Programs
CDER, FDA |
9:05am - 9:20am |
Compliance Overview |
Deborah M. Autor, Esq.
Director
Office of Compliance
CDER, FDA |
9:20am - 10:15am |
New Drugs and Labeling Compliance |
Kathleen R. Anderson, Pharm. D.
Acting Director
Division of New Drugs and Labeling Compliance
Office of Compliance
CDER, FDA |
|
- Internet and Health Fraud Team
|
Linda E. Silvers, DVM, MPH
Acting Associate Director
Division of New Drugs and Labeling Compliance
Office of Compliance
CDER, FDA |
|
|
John P. Loh
Team Leader
New Drugs and Labeling Team
Division of New Drugs and Labeling Compliance
Office of Compliance
CDER, FDA |
|
|
Robert A. Eshelman
OTC Drugs Team
Division of New Drugs and Labeling Compliance
Office of Compliance
CDER, FDA |
|
- Imports, Exports and PDMA Team
|
Ada Irizarry
Team Leader
Import-Export Team
Division of New Drugs and Labeling Compliance
Office of Compliance
CDER, FDA |
|
|
Samia M. Nasr, R.Ph., M.S.
Team Leader
Compounding Team
Division of New Drugs and Labeling Compliance HFD-317
Office of Compliance
CDER, FDA |
10:15am - 10:30am |
Break |
|
10:30am - 11:30am |
Drug Manufacturing and Product Quality |
Grace E. McNally
Acting Deputy Division Director
Drug Manufacturing and Product Quality
Office of Compliance
CDER, FDA |
11:30am - 1:00pm |
Lunch |
|
1:00pm - 2:00pm |
Compliance Risk Management and Surveillance |
John W. Gardner, MD, DrPH
Director, Div. Compliance Risk Management & Surveillance
Office of Compliance
CDER, FDA |
2:00pm - 3:00pm |
Scientific Investigations |
Constance Lewin, MD, MPH
Branch Chief, Good Clinical Practice Branch 1
Division of Scientific Investigations
Office of Compliance
CDER, FDA |
3:00pm - 3:15pm |
Break |
|
3:15pm - 4:00pm |
Inspectional Process and Good Laboratory Practices |
Ruark Lanham
Investigator / Program Expert
Division of Field Investigations
Office of Regional Operations
Office of Regulatory Affairs, FDA |
Thursday, September 28, 2006 Pharmocovigilance and Generic Drugs |
9:00am - 9:15am |
Welcome |
Justina A. Molzon, M.S. Pharm., J.D.
Associate Director
International Programs
CDER, FDA |
9:15am - 10:30am |
Overview of Drug Safety (Dal Pan) |
Gerald Dal Pan, M.D.
Director
Office of Surveillance and Epidemiology
CDER, FDA |
10:30am - 11:00am |
Medication Errors |
Denise Toyer
Deputy Director
Division of Medication Errors and Technical Support
Office of Drug Safety
CDER, FDA |
11:00am - 11:15am |
Break |
|
11:15am - 12:15pm |
Drug Marketing, Advertising, and Communications |
Marci Kiester, Pharm.D.
LCDR, United States Public Health Service
Group Leader
Division of Drug Marketing, Advertising, and Communications
Office of Medical Policy
CDER, FDA |
12:15pm - 1:45pm |
Lunch |
|
1:45pm - 2:15pm |
Public Service Campaigns |
John Friel, J.D.
Deputy Director
Office of Training and Communications
CDER, FDA |
2:15pm - 3:00pm |
Overview of the Generic Drug Process |
Ted Sherwood
Management Analyst
Office of Pharmaceutical Science
CDER, FDA |
3:00pm - 3:30pm |
Chemistry |
Richard Adams
Deputy Director
Division of Chemistry II
Office of Generic Drugs
Office of Pharmaceutical Sciences
CDER, FDA |
3:30pm - 3:45pm |
Break |
|
3:45pm - 4:30pm |
BioEquivalence |
Shirley K. Lu, Ph.D.
Division of Bioequivalence
Office of Generic Drugs
CDER, FDA
Barbara M. Davit, J.D., Ph.D.
Deputy Director, Division of Bioequivalence
Office of Generic Drugs |
4:30pm - 5:00pm |
Web Developments at CDER |
Monica Unger, M.L.S.
Web Project Manager
Division of Information Services
Office of Training and Communications
CDER, FDA |